TrialJAMA network open2022

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.

Jing He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.